Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin

Vaccine

Volumn 28, Issue 13, 2010, Pages 2565-2572

  Smith, Larry R ^a   Wloch, Mary K ^a   Ye, Ming ^a   Reyes, Luane R ^a   Boutsaboualoy, Souphaphone ^a   Dunne, Casey E ^a   Chaplin, Jennifer A ^a   Rusalov, Denis ^a   Rolland, Alain P ^a   Fisher, Cindy L ^a   Al Ibrahim, Mohamed S ^b   Kabongo, Martin L ^c   Steigbigel, Roy ^d   Belshe, Robert B ^e   Kitt, Ernest R ^a   Chu, Alice H ^a   Moss, Ronald B ^a  

^a VICAL INC   (United States)

^b SNBL Ltd   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e SAINT LOUIS UNIVERSITY   (United States)

Author keywords

DNA vaccine; H5N1 influenza virus; Vaxfectin

Indexed keywords

DNA VACCINE; INFLUENZA VACCINE; INFLUENZA VACCINE ADJUVANTED PLASMID DNA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PLACEBO; TRIPLE VACCINE; UNCLASSIFIED DRUG; VAXFECTIN;

ANTIBODY RESPONSE; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; MALAISE; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN INDURATION; SWELLING; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MALE; PHOSPHATIDYLETHANOLAMINES; PLACEBOS; PLASMIDS; RNA-BINDING PROTEINS; T-LYMPHOCYTES; VACCINES, DNA; VIRAL CORE PROTEINS; VIRAL MATRIX PROTEINS;

EID: 77649188963     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.029     Document Type: Article

References (27)

1. Abdel-Ghafar A.N., Chotpitayasunondh T., Gao Z., Hayden F.G., Nguyen D.H., de Jong M.D., et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358 (2008) 261-273
2. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 (2006) 1657-1664
3. Keitel W.A., Campbell J.D., Treanor J.J., Walter E.B., Patel S.M., He F., et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 198 (2008) 1309-1316
4. Nolan T.M., Richmond P.C., Skeljo M.V., Pearce G., Hartel G., Formica N.T., et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26 (2008) 4160-4167
5. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 (2006) 1343-1351
6. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K.B., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197 (2008) 667-675
7. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358 (2008) 2573-2584
8. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 (2007) 580-589
9. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A.D., Vandermeulen C., Forgus S., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198 (2008) 642-649
10. Keitel W.A., and Atmar R.L. Preparing for a possible pandemic: influenza A/H5N1 vaccine development. Curr Opin Pharmacol 7 (2007) 484-490
11. Epstein S.L., Tumpey T.M., Misplon J.A., Lo C.Y., Cooper L.A., Subbarao K., et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8 (2002) 796-801
12. Jimenez G.S., Planchon R., Wei Q., Rusalov D., Geall A., Enas J., et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 3 (2007) 157-164
13. Lalor P.A., Webby R.J., Morrow J., Rusalov D., Kaslow D.C., Rolland A., et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 197 (2008) 1643-1652
14. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., and Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5 (1999) 1157-1163
15. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259 (1993) 1745-1749
16. Hartikka J., Bozoukova V., Ferrari M., Sukhu L., Enas J., Sawdey M., et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19 (2001) 1911-1923
17. Reyes L., Hartikka J., Bozoukova V., Sukhu L., Nishioka W., Singh G., et al. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 19 (2001) 3778-3786
18. Kroger A.T., Atkinson W.L., Marcuse E.K., and Pickering L.K. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 (2006) 1-48
19. Stephenson I., Wood J.M., Nicholson K.G., Charlett A., and Zambon M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103 (2004) 91-95
20. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 (1999) 937-943
21. Wloch M.K., Smith L.R., Boutsaboualoy S., Reyes L., Han C., Kehler J., et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 197 (2008) 1634-1642
22. Lee L.Y., Ha do L.A., Simmons C., de Jong M., Vinh Chau N.V., Schumacher R., et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118 (2008) 3478-3490
23. Rumke H.C., Bayas J.M., de Juanes J.R., Caso C., Richardus J.H., Campins M., et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 26 (2008) 2378-2388
24. FDA. Guidance for industry clinical data needed to support the licensure of pandemic influenza vaccines; 2007. Available at: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074770.htm [accessed October 8, 2009].
25. Epstein S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193 (2006) 49-53
26. Belshe R.B. Implications of the emergence of a novel H1 influenza virus. N Engl J Med 360 (2009) 2667-2668
27. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 21 (2003) 1776-1779